Announcements Trials
Browse Landscape

Phase

Phase 2 139Phase 3 42Phase 1 35Phase 1/2 26Phase 2/3 4Phase 4 3Phase NA 2Phase EARLY_PHASE1 1

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 15Breast 5Tumor-Agnostic 3Gynecologic 3Thoracic 2Other solid neoplasm 1

Conditions

Ovarian Neoplasms 2Peritoneal Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 10human papillomavirus vaccine, L1 type 16, 18 7olaparib 4niraparib 4Human Papillomavirus Recombinant Vaccine nonavalent 4Vaccines 3Saline Solution 3Papillomavirus Vaccines 3Medroxyprogesterone Acetate 3Carboplatin 3Bevacizumab 3pegylated granulocyte colony-stimulating factor 2liposomal doxorubicin 2fluciclovine F-18 2apatinib 2Sevoflurane 2Propofol 2Paclitaxel 2Aspirin 2semaglutide 1pegfilgrastim 1pazopanib 1palbociclib 1lenvatinib 1halofantrine 1ganirelix 1gadofosveset trisodium 1fosaprepitant 1follicle stimulating hormone, human, with HCG C-terminal peptide 1ferrous gluconate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Bevacizumab × Gynecologic × Clear all
NCT06121401 2025-09-17

IOLANTHE

Mario Negri Institute for Pharmacological Research

Phase 4 Active not recruiting
190 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT01932125 2025-06-26

An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Hoffmann-La Roche

Phase 4 Completed
100 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT01706120 2023-03-24

MITO16/MANGO-2

National Cancer Institute, Naples

Phase 4 Unknown
400 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡